Haemonetics (HAE) Share-based Compensation (2009 - 2026)

Haemonetics' Share-based Compensation history runs 18 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 31.57% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $33.8 million (up 14.14% YoY), while the FY2026 annual figure was $33.8 million, up 14.14% from the prior year.
• Share-based Compensation was $9.1 million for Q1 2026 at Haemonetics, up from $7.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.3 million in Q2 2025 to a low of $5.1 million in Q2 2022.
• Historically, Share-based Compensation has averaged $7.2 million across 5 years, with a median of $7.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation retreated 28.31% in 2022, then surged 38.47% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $7.5 million in 2022, then dropped by 3.66% to $7.2 million in 2023, then climbed by 13.81% to $8.2 million in 2024, then fell by 5.05% to $7.8 million in 2025, then climbed by 17.03% to $9.1 million in 2026.
• The last three Share-based Compensation figures came in at $9.1 million (Q1 2026), $7.8 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.